Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
DomainSpectrin/alpha-actinin

AKAP6 TRIO

5.85e-0432212IPR018159
DomainSPEC

AKAP6 TRIO

5.85e-0432212SM00150
Domain-

PAN2 POLE

1.26e-03472123.30.420.10
DomainRNaseH-like_dom

PAN2 POLE

2.70e-0369212IPR012337
DomainKRAB

ZNF7 ZNF544 SSX8P

7.19e-03358213PF01352
DomainKRAB

ZNF7 ZNF544 SSX8P

7.81e-03369213SM00349
DomainKRAB

ZNF7 ZNF544 SSX8P

7.87e-03370213IPR001909
DomainI-set

TRIO SIGLEC1

1.90e-02190212PF07679
DomainIg_I-set

TRIO SIGLEC1

1.90e-02190212IPR013098
Pubmed

A non-proteolytic role for ubiquitin in deadenylation of MHC-I mRNA by the RNA-binding E3-ligase MEX-3C.

PAN2 ZNF574

3.89e-044423226471122
ComputationalNeighborhood of ERCC4

TRIO SYNJ2 APOBEC1 C1orf216

2.18e-04321114MORF_ERCC4
ComputationalNeighborhood of RAD51L3

TRIO SYNJ2 APOBEC1 C1orf216

4.46e-04387114MORF_RAD51L3
ComputationalNeighborhood of FOSL1

TRIO SYNJ2 APOBEC1 C1orf216

5.36e-04406114MORF_FOSL1
ComputationalNeighborhood of MAGEA9

TRIO SYNJ2 APOBEC1 C1orf216

6.26e-04423114MORF_MAGEA9
ComputationalNeighborhood of PAX7

TRIO SYNJ2 C1orf216

2.13e-03266113MORF_PAX7
ComputationalNeighborhood of MDM2

TRIO APOBEC1 C1orf216

2.45e-03279113MORF_MDM2
ComputationalNeighborhood of FSHR

TRIO APOBEC1 C1orf216

2.45e-03279113MORF_FSHR
ComputationalNeighborhood of NOS2A

TRIO SYNJ2 C1orf216

2.68e-03288113MORF_NOS2A
ComputationalNeighborhood of CCNF

SYNJ2 C1orf216

2.74e-0378112MORF_CCNF
ComputationalNeighborhood of RFC5

SYNJ2 C1orf216

2.74e-0378112MORF_RFC5
ComputationalNeighborhood of ARL3

TRIO SYNJ2 C1orf216

3.12e-03304113MORF_ARL3
ComputationalNeighborhood of SUPT3H

TRIO APOBEC1 C1orf216

3.87e-03328113MORF_SUPT3H
ComputationalNeighborhood of ATF2

TRIO APOBEC1 C1orf216

3.94e-03330113MORF_ATF2
DrugABMP

IFNK LYST SIGLEC1

2.31e-0626233CID000080567
DrugMexiletine hydrochloride [5370-01-4]; Up 200; 18.6uM; MCF7; HT_HG-U133A

AKAP6 TRIO LYST IL17RC

4.07e-051952343862_UP
DrugRiluzole hydrochloride; Up 200; 14.8uM; PC3; HT_HG-U133A

CTRC TRIO HS3ST1 IL17RC

4.23e-051972343666_UP
DrugBetulinic acid [472-15-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A

AKAP6 TRIO HS3ST1 SYNJ2

4.23e-051972344181_UP
DrugThioperamide maleate [106243-16-7]; Down 200; 9.8uM; MCF7; HT_HG-U133A

SYNJ2 LYST RHOBTB2 ZNF574

4.40e-051992345635_DN
Drug3-Cl

CTRC SIGLEC1

2.03e-0421232CID000012313
DrugAC1NUUB8

CTRC LYST

4.46e-0431232CID005493639
DrugCHEMBL466993

IFNK SIGLEC1

4.75e-0432232CID005320808
DrugAC1NMVIZ

LYST SIGLEC1

5.37e-0434232CID005057842
DrugBT325

SYNJ2 LYST

6.02e-0436232CID000068933
DrugCytosar-U

IFNK POLE APOBEC1 SIGLEC1

6.32e-04399234CID000000596
DrugFim 1

LYST SIGLEC1

6.36e-0437232CID000132906
DrugDigoxin [20830-75-5]; Down 200; 5.2uM; HL60; HT_HG-U133A

ZNF7 LYST RHOBTB2

8.04e-041832332423_DN
DrugNaringenine [480-41-1]; Down 200; 14.6uM; MCF7; HT_HG-U133A

TRIO SYNJ2 LYST

8.55e-041872333278_DN
DrugC768-0445; Up 200; 10uM; MCF7; HT_HG-U133A_EA

TRIO LYST IL17RC

8.69e-04188233865_UP
DrugImipramine hydrochloride [113-52-0]; Up 200; 12.6uM; PC3; HT_HG-U133A

TRIO HS3ST1 LYST

8.82e-041892331807_UP
DrugLanatoside C [17575-22-3]; Down 200; 4uM; HL60; HT_HG-U133A

ZNF7 SYNJ2 RHOBTB2

8.96e-041902332193_DN
DrugTriflupromazine hydrochloride [1098-60-8]; Up 200; 10.2uM; PC3; HT_HG-U133A

ZNF7 TRIO PAN2

9.09e-041912331813_UP
DrugClotrimazole [23593-75-1]; Down 200; 11.6uM; PC3; HT_HG-U133A

SYNJ2 IL17RC RHOBTB2

9.37e-041932335726_DN
Drug0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A

CTRC TRIO SYNJ2

9.37e-041932334289_UP
Drugrapamycin, Streptomyces hygroscepicus; Up 200; 0.1uM; PC3; HT_HG-U133A

TRIO SYNJ2 IL17RC

9.37e-041932335932_UP
DrugPiromidic acid [19562-30-2]; Down 200; 13.8uM; HL60; HT_HG-U133A

SYNJ2 RHOBTB2 ZNF574

9.37e-041932332996_DN
Drugnordihydroguaiaretic acid; Down 200; 1uM; PC3; HT_HG-U133A

SYNJ2 POLE ZNF574

9.51e-041942331223_DN
DrugLY 294002; Up 200; 10uM; HL60; HT_HG-U133A

CTRC TRIO IL17RC

9.51e-041942332687_UP
DrugDoxazosin mesylate [77883-43-3]; Down 200; 7.4uM; PC3; HT_HG-U133A

HS3ST1 SYNJ2 ZNF574

9.51e-041942336642_DN
DrugRoxarsone [121-19-7]; Down 200; 15.2uM; PC3; HT_HG-U133A

TRIO HS3ST1 IL17RC

9.51e-041942335051_DN
DrugTranexamic acid [1197-18-8]; Down 200; 25.4uM; PC3; HT_HG-U133A

SYNJ2 LYST RHOBTB2

9.51e-041942335762_DN
DrugHeptaminol hydrochloride [543-15-7]; Down 200; 22uM; HL60; HT_HG-U133A

SYNJ2 LYST ZNF574

9.66e-041952331866_DN
DrugMetaraminol bitartrate [33402-03-8]; Down 200; 8.6uM; MCF7; HT_HG-U133A

TRIO IL17RC ZNF574

9.66e-041952334692_DN
DrugOxamniquine [21738-42-1]; Up 200; 14.4uM; HL60; HT_HG-U133A

AKAP6 IL17RC ZNF574

9.66e-041952332924_UP
DrugBumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A

HS3ST1 SYNJ2 RHOBTB2

9.66e-041952335117_DN
DrugDyclonine hydrochloride [536-43-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A

SYNJ2 LYST IL17RC

9.66e-041952337022_UP
DrugOxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A

SYNJ2 LYST RHOBTB2

9.66e-041952332278_DN
DrugCarbimazole [22232-54-8]; Down 200; 21.4uM; MCF7; HT_HG-U133A

LYST IL17RC ZNF574

9.66e-041952335399_DN
DrugEthotoin [86-35-1]; Up 200; 19.6uM; MCF7; HT_HG-U133A

AKAP6 LYST APOBEC1

9.66e-041952336052_UP
DrugKaempferol [520-18-3]; Up 200; 14uM; MCF7; HT_HG-U133A

SYNJ2 LYST RHOBTB2

9.80e-041962333579_UP
DrugLomefloxacin hydrochloride [98079-52-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A

TRIO SYNJ2 LYST

9.94e-041972334745_DN
DrugBetahistine mesylate [54856-23-4]; Down 200; 17.2uM; PC3; HT_HG-U133A

TRIO SYNJ2 ZNF574

9.94e-041972336611_DN
DrugScopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; MCF7; HT_HG-U133A

SYNJ2 LYST RHOBTB2

9.94e-041972335436_DN
Drugradicicol; Down 200; 0.1uM; PC3; HG-U133A

CTRC TRIO SYNJ2

9.94e-04197233449_DN
DrugRauwolscine hydrochloride [6211-32-1]; Down 200; 10.2uM; PC3; HT_HG-U133A

PAN2 SYNJ2 RHOBTB2

9.94e-041972335800_DN
DrugDubinidine [22964-77-8]; Up 200; 14.6uM; MCF7; HT_HG-U133A

LYST RHOBTB2 EXTL1

9.94e-041972333554_UP
DrugSolasodine [126-17-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A

CTRC RHOBTB2 EXTL1

9.94e-041972333924_UP
DrugMeptazinol hydrochloride [59263-76-2]; Down 200; 14.8uM; PC3; HT_HG-U133A

SYNJ2 IL17RC RHOBTB2

9.94e-041972334188_DN
DrugPyrilamine maleate [59-33-6]; Up 200; 10uM; MCF7; HT_HG-U133A

TRIO HS3ST1 APOBEC1

9.94e-041972333184_UP
DrugFlutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A

SYNJ2 IL17RC RHOBTB2

9.94e-041972333885_DN
DrugNalbuphine hydrochloride [23277-43-2]; Up 200; 10.2uM; MCF7; HT_HG-U133A

TRIO LYST RHOBTB2

9.94e-041972337177_UP
DrugSuprofen [40828-46-4]; Up 200; 15.4uM; HL60; HT_HG-U133A

AKAP6 CTRC APOBEC1

1.01e-031982333005_UP
DrugCarbenoxolone disodium salt [7421-40-1]; Down 200; 6.6uM; PC3; HT_HG-U133A

TRIO SYNJ2 RHOBTB2

1.01e-031982334093_DN
DrugIndapamide [26807-65-8]; Up 200; 10.6uM; PC3; HT_HG-U133A

AKAP6 CTRC EXTL1

1.01e-031982333778_UP
DrugAmidopyrine [58-15-1]; Down 200; 17.2uM; MCF7; HT_HG-U133A

TRIO SYNJ2 RHOBTB2

1.01e-031982336818_DN
Drugnordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A

TRIO SYNJ2 RHOBTB2

1.01e-031982335220_UP
DrugAmprolium hydrochloride [137-88-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

TRIO SYNJ2 ZNF574

1.01e-031982331479_DN
DrugPhenformin hydrochloride [834-28-6]; Up 200; 16.6uM; MCF7; HT_HG-U133A

TRIO HS3ST1 EXTL1

1.01e-031982332312_UP
DrugNalidixic acid sodium salt hydrate; Down 200; 14.6uM; MCF7; HT_HG-U133A

SYNJ2 IL17RC ZNF574

1.01e-031982332297_DN
DrugGlibenclamide [10238-21-8]; Up 200; 8uM; MCF7; HT_HG-U133A

TRIO SYNJ2 IL17RC

1.01e-031982333163_UP
DrugEpivincamine [6835-99-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A

TRIO IL17RC RHOBTB2

1.01e-031982336838_DN
DrugFolinic acid calcium salt [6035-45-6]; Up 200; 7.8uM; PC3; HT_HG-U133A

TRIO IL17RC RHOBTB2

1.01e-031982333703_UP
DrugCaffeic acid [3331-39-5]; Down 200; 22.2uM; MCF7; HT_HG-U133A

ZNF7 TRIO SYNJ2

1.01e-031982335352_DN
DrugAtropine-N-oxide hydrochloride [4574-60-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A

LYST IL17RC RHOBTB2

1.01e-031982332216_UP
DrugTiclopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; PC3; HG-U133A

SYNJ2 LYST SIGLEC1

1.01e-031982331895_UP
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Down 200; 10.4uM; MCF7; HT_HG-U133A

TRIO PAN2 ZNF574

1.01e-031982337417_DN
DrugNeostigmine bromide [114-80-7]; Down 200; 13.2uM; MCF7; HT_HG-U133A

SYNJ2 C1orf216 ZNF574

1.01e-031982335335_DN
DrugNaloxone hydrochloride [357-08-4]; Up 200; 11uM; PC3; HT_HG-U133A

HS3ST1 SYNJ2 SIGLEC1

1.01e-031982334645_UP
DrugBetahistine mesylate [54856-23-4]; Up 200; 17.2uM; HL60; HT_HG-U133A

AKAP6 CTRC TRIO

1.01e-031982332472_UP
DiseasePeripheral Nervous System Diseases

LYST RHOBTB2

6.75e-0454212C4721453
Diseaseankylosing spondylitis

AKAP6 HS3ST1

1.90e-0391212EFO_0003898
DiseaseIntellectual Disability

AKAP6 TRIO RHOBTB2

3.75e-03447213C3714756

Protein segments in the cluster

PeptideGeneStartEntry
SRRWQNHLTFFRLHL

APOBEC1

196

P41238
RRLALLQWIRGLQHQ

C1orf216

176

Q8TAB5
RLIQRWNRFILTQLH

PAN2

611

Q504Q3
LQRLLWVRQAATLNH

DUSP13

31

Q9UII6
LFFARHLQRHNHLLW

POLE

1671

Q07864
FANHTIQIRQDWRHL

METTL21A

26

Q8WXB1
TIHVHKRWNALLLRN

CTRC

106

Q99895
NLLNVHLRRVTWQNL

IFNK

31

Q9P0W0
RHWQELIQQLTHDRA

LYST

2921

Q99698
RAHQNLWQAARLQLL

IL17RC

366

Q8NAC3
QNWLRFFPLRHIHIV

HS3ST1

201

O14792
FWNQLLHVPLRQHQV

SYNJ2

161

O15056
RRHLQFWKSHLRNVQ

RHOBTB2

211

Q9BYZ6
LQWNRGRNHLVLRLH

EXTL1

151

Q92935
IVDIHAVQLLWHQLR

AKAP6

141

Q13023
LWLFRQHHQVPLALV

TLCD2

186

A6NGC4
HLQHLAQRLQWNRRA

SPART-AS1

6

P0CW21
HAWTHRLRERNQLVI

SSX8P

161

Q7RTT4
ASQELWLNHRQTHLR

ZNF574

136

Q6ZN55
RALHRLHQFQQLLWV

SIGLEC1

1631

Q9BZZ2
SFRWNSNLVIHQRIH

ZNF544

556

Q6NX49
HRHLFIQQLLRTCWP

WWC2-AS2

121

Q96NR7
LENIWQHRKVRLHQR

TRIO

551

O75962
AFRWISRLSQHQLIH

ZNF7

421

P17097